CN1786031B - Glucagon kind polypeptide-1 analogue, its preparation method and application - Google Patents

Glucagon kind polypeptide-1 analogue, its preparation method and application Download PDF

Info

Publication number
CN1786031B
CN1786031B CN 200510102363 CN200510102363A CN1786031B CN 1786031 B CN1786031 B CN 1786031B CN 200510102363 CN200510102363 CN 200510102363 CN 200510102363 A CN200510102363 A CN 200510102363A CN 1786031 B CN1786031 B CN 1786031B
Authority
CN
China
Prior art keywords
gly
ala
ser
glu
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 200510102363
Other languages
Chinese (zh)
Other versions
CN1786031A (en
Inventor
李弘剑
周天鸿
苏正定
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan University
University of Jinan
Original Assignee
Jinan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan University filed Critical Jinan University
Priority to CN 200510102363 priority Critical patent/CN1786031B/en
Publication of CN1786031A publication Critical patent/CN1786031A/en
Application granted granted Critical
Publication of CN1786031B publication Critical patent/CN1786031B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The present invention discloses a glucagons-like polypeptide-1 analog, its preparation method and application. Said invention provides a glucagons-like polypeptide-1 analog whose fifth position, sixth position, eighth position, thirty-fourth position, thirty-fifth position and/or thirty-seventh position are modified. Said invention provides chemical preparation and separation method of said polypeptide, and provides the method for preparing and purifying said polypeptide by adopting recombination DNA technique. Said polypeptide can be used for curing diabetes B and obesity.

Description

Glucagon kind polypeptide-1 analogue and preparation method thereof and application
Technical field
The present invention relates to biological technical field, be specifically related to glucagon kind polypeptide-1 (GLP-1) analogue and preparation method thereof and application.
Background technology
At present, diabetes B becomes global disease owing to sickness rate improves.The pathogeny of diabetes B is very complicated, the treatment diabetes B medicine of current use has many disadvantages, the main life-time service that shows causes patient's weight increase, and because the loss gradually of drug-induced beta cell function makes ill increasing the weight of.About 90 percent diabetic subject is a diabetes B, also is called non-insulin-dependent diabetes mellitus (NIDDM) (NIDDM).The diabetes B patient is excreting insulin still generally, but Regular Insulin can't use effectively by soma, thereby can't the lowering blood glucose level.
Glucagon-like peptide 1 is the normal secrete polypeptide of body, owing to the newtype drug that the evident in efficacy of diabetes B and the defective that can overcome existing medicine is become the treatment diabetes B that attracts tremendous attention.
Glucagon-like peptide 1 (GLP-1) is found in 1984, is considered to a kind of important intestines hypoglycemic element (incretin).Glucagon-like peptide 1 is the product of hyperglycemic-glycogenolytic factor protogene. glucagon-like peptide 1 is to be discharged by the L-cell of enteron aisle when ingesting, and promotes pancreas beta cell uelralante.The effect of glucagon-like peptide 1 not only is to stimulate the release of Regular Insulin, also has other numerous functions.Generally believe that at present glucagon-like peptide 1 not only controls blood-glucose but also advancing by several other effect control diabetes B diseases.
Clinically, it is very effective that glucagon-like peptide 1 is proved to be reducing blood-glucose, and can be used on any stage of diabetes.Very important discovery is seldom to observe hypoglycemic risk.Its reason is that glucagon-like peptide 1 is different from sulfonylurea antidiabetic drug (sulfonylureas), only stimulates the insulin secretion of glucose induction.Utilize natural glucagon-like peptide 1 to carry out six all skin test injections and show that patient's body weight has also descended.Unique known drug side effect is as patient when using the high dosage glucagon-like peptide 1 nausea and vomiting to be arranged.These unnecessary side effects can be used on an empty stomach by being under an embargo and overcome.And most of clinical datas show, it is of short duration feeling sick, and high efficiency glucose control can realize under this side effect situation not having.Thereby from clinical point, glucagon-like peptide 1 can be fallen blood-glucose effectively, and the potentiality of less hypoglycemia risk and prevention disease progression are the ideal medicament of therapeutic type 2 diabetes.
There is two glucagon-like sample peptides, 1 compound carrying out clinical development at present.One class is natural glucagon-like peptide 1.Another kind of is exendin-4, be a kind of from the venom of lizard Heloderma Suspectum isolated polypeptide.This two classes polypeptide structure homology is up to 53%.
Human glucagon-like-peptide-1 1 is the polypeptide that contains 37 amino-acid residues, derives from terminal ileum, derives by glucagon-like peptide is former.In the L-cell, former glucagon-like-peptide-1 (the 7-36)-NH that is processed to of glucagon-like peptide 2, glucagon-like-peptide-1 (3-37) and glucagon-like-peptide-2.Natural human glucagon-like-peptide-1 1 with function has two kinds of forms: glucagon-like-peptide-1 (7-36)-NH 2, glucagon-like-peptide-1 (3-37).
Glucagon-1 (7-36) NH 2Have several uniquenesses and useful effect as potential treatment diabetes B medicine.But because by rapidly hydrolysis and removed rapidly by kidney of pepx IV (DPP IV), the transformation period that natural glucagon-like-peptide-1 acts in vivo extremely short is less than 2 minutes.Disclose other lytic enzyme on evidence, such as neutral endopeptidase (NEP) glucagon-like peptide 1 of also degrading.Thereby hindered and utilized the researchdevelopment of glucagon-like-peptide-1 treatment diabetes B.
Comparatively speaking, exendin-4 has strong resistivity to DPP-IV and NEP hydrolysis, and the transformation period in human body is 26 minutes after DPP-IV control.In the Exendin-4 analogue, the 8th L-Ala is substituted by Gly, and is although the glucagon-like-peptide-1 after replacing has weakened the avidity with acceptor slightly, more stable to DPP IV.According to the exendin-4 aminoacid sequence, can obtain the peptide molecule of more antienzymes, but perhaps these peptide molecules cause immune response.
Undoubtedly, be that the ideal mode of the treatment of target is to use the polypeptide compound derivative with the glucagon-like peptide 1 acceptor.Thereby novel drugs is found, and will to be that exploitation is a kind of have long half time and stable compound.Experimental result shows that the N-terminal sequence of glucagon-like peptide 1 peptide is responsible for the high affinity combination to the core position of glucagon-like peptide 1 acceptor, and its C-end is responsible for selectivity and is combined with the N-end of acceptor; Beta Alanine scans experiment and shows natural glucagon-like peptide 1 the 7th, 10,12,13, and 15,28 and 29 amino acid is to the sensitivity that makes a variation.A large amount of early stage researchs are to aim at the glucagon-like peptide 1 of design protease inhibitor, in order to being used as medicine.But these glucagon-like peptide 1 analogues still can't be used as drug candidate, because they are promptly still removed by kidney.Thereby requirement improves certain time delay of polypeptide compound with other form.
With regard to glucagon-like peptide 1, maximum challenge is that these peptides must be injected.Another more concrete challenge is that a kind of successful glucagon-like peptide 1 medicine should reduce the side effect to esophagus as much as possible.This pharmacology side effect is exactly feeling sick when occurring in drug level and peaking.According to the research of the character of the pharmacokinetics that is associated therewith, the long half-lift can avoid nauseating best because the long half-lift can guarantee minimum dosage in the blood plasma.Show that with the clinical study data pancreas hyperglycemia sample peptide-1 has huge prospect as a kind of non-insulin-dependent diabetes mellitus (NIDDM) for the treatment of before clinical in a large number, particularly particularly remarkable when the oral medicine agent is failed.
In addition, the real clinical potentiality of glucagon-like peptide 1 are to reduce glucose, management of body weight, and disease controlling.Pancreas hyperglycemia sample peptide-1 can be induced many biological effects, for example stimulates insulin secretion, and restrains glucagon secretion, restrains the stomach turned letter, improves glucose utilization, and causes loss of weight.And present clinical study shows, pancreas hyperglycemia sample peptide-1 may stop the deterioration process of the beta cell function damage that diabetes follow.The obvious characteristics of pancreas hyperglycemia sample peptide-1 is that it can stimulate insulin secretion but does not have the hypoglycemia risk, and this risk is common in the therapeutic process that insulin treatment or oral pharmaceutical increase insulin expression.
Summary of the invention
The objective of the invention is to overcome the extremely short problem of transformation period that natural glucagon-like-peptide-1 acts in vivo, a kind of new glucagon kind polypeptide-1 analogue is provided.New derivative has the better medicament effect than natural type; Than natural type resistibility stronger in blood, has longer persistence to DPP-IV; Also easier preparation.
Another object of the present invention provides the preparation method of above-mentioned glucagon-like-peptide-1 analogue.
Further purpose of the present invention provides above-mentioned glucagon kind polypeptide-1 analogue and is used for the treatment of application in the slow releasing pharmaceutical of diabetes B in preparation.
Glucagon kind polypeptide-1 analogue of the present invention has following aminoacid sequence:
Xaa 5-Xaa 6-His-Xaa 8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Xaa 34-Xaa 35-Arg-Xaa 37
Or the acceptable salt of pharmacology;
Wherein:
Xaa 5Be Pro, Gly, Ac, NH 2Perhaps lack;
Xaa 6Be Pro, Ala, Ser or disappearance;
Xaa 8Be Ala, β Ala, Gly, Cys ,-NH-CH (CH 3)-CH 2-,-NH-CH 2-CH 2-, Cys (Acm) or Cys (SO 3);
Xaa 34Be Lys or Pro or disappearance;
Xaa 35Be Gly or Pro or disappearance;
Xaa 37Be β Ala, Met, homoserine, Gly, Asp, NH 2Perhaps lack;
But described glucagon kind polypeptide-1 analogue does not comprise following sequence:
GLP-1(7-37)OH，GLP-1(7-36)NH 2，Gly 8-GLP-1(7-37)OH，Gly 8-GLP-1(7-36)NH 2。
Glucagon kind polypeptide-1 analogue of the present invention has similarly aminoacid sequence of same glucagon kind polypeptide-1 (GLP-1 (7-37) OH).The aminoacid sequence of GLP-1 (7-37) OH sees Table the SEQ ID NO:2 in 1.Pancreas hyperglycemia sample peptide-1 analogue is being revised the amino acid of one or more positions, and as after the 8th and the 37th amino acids, displaying has than natural pancreas hyperglycemia sample peptide-1 (7-37) OH stronger vigor is arranged.Glucagon kind polypeptide-1 analogue of the present invention and GLP-1 (7-37) OH and GLP-1 (7-36) NH 2Sufficient homology is arranged, and glucagon kind polypeptide-1 analogue possesses insulinotropic activity.Described glucagon kind polypeptide-1 analogue includes GLP-1 (7-37) OH aminoacid sequence or revises the corresponding position of GLP-1 (7-37) OH amino acid so that analogue has one, two, three, four or five amino acid be different from GLP-1 (7-37) OH.The name of glucagon kind polypeptide-1 analogue with the location column of alternate amino acid and it before maternal structure, as table 2 to shown in the table 6.For example, Cys 8-GLP-1 (7-37) OH is a kind of glucagon kind polypeptide-1 analogue that is replaced by halfcystine among GLP-1 (7-37) OH at the 8th L-Ala.As shown in table 2, glucagon kind polypeptide-1 analogue of the present invention is 8 to be a series of analogues of non-L-Ala in the position, i.e. position 8 analogues.
Glucagon kind polypeptide-1 analogue of the present invention is the polypeptide that contains about 30 or 32 natural or alpha-non-natural amino acids, and and glucagon kind polypeptide-1 (7-37) OH sufficient homology is arranged, and have the insulin secretagogue activity." insulin secretagogue activity " refers to that the ability of stimulating insulin secretion can respond the glucose level of rising, and the glucose of rising is absorbed by cell, causes that glucose reduces to normal level in the blood plasma.The insulin secretagogue activity can comprise the activation of using interior experiment of body and analyzed in vitro to measure glucagon kind polypeptide-1 receptors bind avidity or acceptor by the currently known methods analysis.Interpretation of result sees Table 7.
Can be by being connected Xaa with the glucagon-like-peptide-1 analogue that the present invention is consistent 37And Xaa 5The cyclic peptide that forms.This cyclic peptide has better medicament kinetics and drug metabolism performance (as shown in table 7) than wire peptide, and cyclic peptide have can be oral advantage.
The glucagon-like-peptide-1 analogue that is consistent with the present invention can be and passes through Cys 5Or Cys 8The dimer peptide that disulfide linkage forms.This dimer peptide has better medicament kinetics and drug metabolism performance (as shown in table 7) than wire peptide.
More specific glucagon kind polypeptide-1 analogue be with GLP-1 (7-37) OH in the position 7 and position 37 amino acid be connected to form a kind of cyclic peptide.Situation is except that replacing the eight amino acid of position better, and position 6 be proline(Pro) or glycine, and position 34 and 35 amino acid are substituted by proline(Pro), and position 37 amino acid are alternative by aspartic acid or glycine.As shown in table 4.
Obtain than the more stable compound of GLP-1 (7-37) OH by above-mentioned position amino acid replacement.As shown in table 7, the transformation period of glucagon kind polypeptide-1 analogue of the present invention obviously will be grown than GLP-1 (7-37) OH, and glucagon kind polypeptide-1 analogue more has vigor than GLP-1 (7-37) OH.Fig. 2 illustrates that mAla8-GLP-1 (7-37)-OH and GLP-1 (7-37) OH relatively have higher vigor.
Glucagon kind polypeptide-1 analogue of the present invention also comprises the salt compounds of acceptable glucagon kind polypeptide-1 analogue on the pharmacology.Glucagon kind polypeptide-1 analogue has competent acid functional group or alkaline functional group, or has the soda acid functional group simultaneously, these functional groups can with the mineral alkali of some amount, mineral acid and organic acid etc. form salt.
In the present invention, one of them is specialized and is, glucagon-like-peptide-1 analogue of the present invention can convert C-end amidation polypeptide to.
Glucagon kind polypeptide-1 analogue of the present invention mainly refers to natural amino acid.
In the present invention, one of them is specialized and is, prepares the glucagon-like-peptide-1 analogue by recombinant DNA method, and expressed peptide is the front and back repeated arrangement.Repeat peptide fragment and connect by methionine(Met) or Asp-Gly or Asp-Pro, maximum several six fragments of peptide fragment that repeat are about to the form that glucagon kind polypeptide-1 analogue repeats to connect with following formula and insert among the protein expression plasmid pMFH:
--{ GLP-1 analogue } n--is n=1-6 wherein.
In the present invention, one of them is specialized and is, utilizes solid phase method to strengthen the purifying of Gluca Gen sample polypeptide-1 analogue.The fusion rotein utilization chemistry that will contain glucagon kind polypeptide-1 analogue earlier is connected in surface of solid phase carriers, discharges polypeptide with chemical hydrolysis again.
A kind of method of utilizing chemistry connection and chemical hydrolysis purifying Gluca Gen sample of the present invention polypeptide-1 analogue may further comprise the steps:
A) standard program that Padil thioesters or alanine thioesters are provided according to supplier under water-less environment is connected to the little bead surface of solid phase;
B) the N terminal design of reorganization fusion vector pMFH has halfcystine, and the fusion rotein that will contain Gluca Gen sample polypeptide-1 analogue is by the covalently bound surface to the solid phase globule of chemical connection method;
C) fusion rotein of Biao Daing in elutriant, adds 4%benzymercaptan by Ni-NTA affinity chromatography column purification, with 4%thiophenol or 2%MESNA to increase the efficient that chemistry is connected;
D) wash the solid phase globule fully with chemical hydrolysates: 0.1 volumetric molar concentration hydrochloric acid, 6 volumetric molar concentration hydrochloric acid guanidines;
E) add cyanogen bromide with 1: 200～400 mol ratios and decompose fusion rotein release Gluca Gen sample polypeptide-1 analogue; Collection merges the elutant that contains polypeptide, uses the C18Sep-Pak reversed-phase column to carry out desalination.
In the steps A, described solid phase globule is preferably the Affi-Gel10 gel of chemically modified.
Glucagon kind polypeptide-1 analogue of the present invention can be used for preparing the slow releasing pharmaceutical for the treatment of diabetes B, and the prototype of its slow releasing pharmaceutical is:
Protein carrier-interlocking matrix-glucagon kind polypeptide-1 analogue;
Described protein carrier is human albumin (Albumin) or other people blood protein;
Described interlocking matrix has following aminoacid sequence:
Yaa1-Yaa2-Yaa3-Yaa4-Yaa5-Yaa6-Yaa7
Wherein:
Yaa1:Cys or disappearance;
Yaa2:Phe or Leu or disappearance;
Yaa3:Asn or Val or disappearance;
Yaa4:Pro or disappearance;
Yaa5:Arg or disappearance;
Yaa6:Gly or Pro or Ala or disappearance;
Yaa7:Ser or Pro or Ala or disappearance.
The present invention utilizes protein carrier slowly-releasing glucagon kind polypeptide-1 analogue in vivo.Glucagon kind polypeptide-1 analogue is connected in protein carrier surface (as human albumin or other people blood protein) by hydrolyzable aminoacid sequence.Hydrolyzable aminoacid sequence can be selected the human thrombin recognition sequence.
Compared with prior art, the present invention has following beneficial effect:
The present invention to novel pancreas hyperglycemia sample peptide-1 analogue that DPP IV has powerful resistance, has solved the extremely short and not high problem of medicine biologicak efficiency of natural pancreas hyperglycemia sample peptide-1 transformation period by exploitation.The present invention also overcomes the limited medicine biologicak efficiency of pancreas hyperglycemia sample peptide-1 by improving non-injection treatment efficient.
Description of drawings
Fig. 1 closes the expression plasmid that technical process prepares the glucagon kind polypeptide-1 compound for gene recombination;
Fig. 2 is the anti-DPP IV of a glucagon kind polypeptide-1 analogue peptidase resistance analytical results;
Fig. 3 represents a kind of with solid phase method reinforcement recombinant polypeptide purification process;
Fig. 4 is a kind of mass spectrometry results of Gluca Gen sample polypeptide-1;
Fig. 5 is the analysis of many peptide-1 derivatives of slowly-releasing Gluca Gen sample slow release effect.
Embodiment
Embodiment 1: solid phase Fmoc chemical method prepares the glucagon kind polypeptide-1 compound
Glucagon kind polypeptide-1 analogue available standards solid-phase peptide synthetic method preparation of the present invention.Peptide synthesizer can be bought from commercial company, as the Applied Biosystems company of California, USA.The polypeptide synthon also can be bought from commercial company, as California, USA NovaBiochem company.The description operation that the use of solid-phase peptide synthesizer provides according to manufacturers is protected the interference group, and even summation reaction is uncoupled and reacted, in conjunction with, separate non-reactive amino acid protective reaction.
The peptides that table 1 is shown in 6 uses the PerSeptive automatic peptide synthesizer to adopt F-moc chemistry solid phase method synthetic.Solid phase carrier is a polyethylene glycol multi-styrene resin; use the piperidines dimethyl formamide for removing protective material and 2-(1H-benzotriazol-1-yl)-1; 1,3,3-tetramethyluroniumhexafluorophosphate and 1-hydroxyben-zotriazole are for linking agent.Initial C-terminal acyl ammonia thing uses 50umole Rink AM resin.After the polypeptide chain place is closed and finished, use 90%TFA, 5%thioanisole, 3%anisol and 2%ethanedithiol remove resin cracking and protective reaction.Thick peptide uses the anti-phase hydrophobic chromatography purifying of C18-HPLC, and moving phase is that the sample that contains the acetonitrile gradient purifying of 0.1% trifluoroacetic acid is identified by mass spectrum.The purity of purified peptide is greater than 95%.
Raw material Fmoc-Ala ψ CH (OH)-CH2-Glu (OtBu) and Fmoc-Gly ψ CH (OH)-CH2-Glu (OtBu) is according to document { Makowiec, the S. ， ﹠amp of Makowiec etc.; Wisniewska, K. ， ﹠amp; Lankiewicz, L. (2004) .Peptide bond modification.I.simple and efficient method of Boc-Gly[CH (OH) CH2] Gly-OH syntesis.Polish J.Chem.78,315-318.} described ordinary method is prepared, other Fmoc amino acid and other chemical preparations and solvent are all bought in commercial source.
Embodiment 2: gene recombination is closed technical process and is prepared the glucagon kind polypeptide-1 compound
Glucagon kind polypeptide-1 analogue of the present invention can prepare with recombinant DNA method.For example, glucagon kind polypeptide-1 gene cocoa is grand in expression of polypeptides carrier pMFH (Su ZD and Ni F.Novelfusion proteins for efficient production of recombinant peptides.PCT/WO2004/015111).Glucagon kind polypeptide-1 in the fused protein is further used the HPLC purifying by after the chemical process cracking.
The glucagon kind polypeptide-1 and the mutant that only contain L-type natural amino acid in the table 1 also can be by documents such as Osborne (Osborne, M.J., Su, Z., Sridaran, V. ， ﹠amp; Ni, F. (2003) .Efficientexpression of isotopically labeled peptides for high resolution NMRstudies:appl ication to the Cdc42/Rac binding domains of virulent kinasesin Candida albicans.J.Biomol.NMR26,317-326.) and the conventional gene recombination technology of closing described of patent (Su ZD andNi F.Novel fusion proteins for efficient production of recombinantpeptides.PCT/WO2004/015111) such as Su prepare.Glucagon kind polypeptide-1 and mutant gene fragment can be inserted among the protein expression plasmid pCMFH, as shown in Figure 1 to reach six repeated fragment forms single or simultaneously.Link by methionine(Met) or Asp-Gly between the fragment.
As described in patents such as document such as above-mentioned Osborne and Su, the carrier protein that uses among the plasmid pSGLP is the mutant fragment of the no methionine(Met) of N-end of staphylococcal nuclease, and binding has six continuous histidine marks.
Fused protein is expressed with e. coli bl21 (DE3).Use the Ni-NTA agarose resin to carry out purifying by standard program then.Fused protein is dissolved in 70% formic acid, utilizes acid or cyanogen bromide hydrolysis to discharge target peptide.Crystal cyanogen bromide usage quantity is 100 times of fused protein mole numbers.Allow reaction mixture under dark state, react 24 hours.Reaction mixture carries out desalting treatment later in neutralisation, and the sample after the desalting treatment is removed MFH fusion vector and unhydrolysed fused protein through Ni NTA chromatography column.Eluent stream freeze-drying after desalination is standby.
Lyophilized powder uses C18HPLC reversed phase chromatography post, is that gradient is carried out wash-out with water and acetonitrile miscellany (containing 0.1% trifluoroacetic acid).Pure peptide is examined by mass spectrum, as shown in Figure 4.
Embodiment 3: utilize solid phase method to strengthen the purification process of recombinant polypeptide
Fig. 3 describes a kind of purification process of strengthening recombinant polypeptide with solid phase method.Solid phase globule 1 is the Affi-Gel10 gel (Bio-Rad, the U.S.) of modified.Although can use other solid phase globule, the Affi-Gel10 gel is to urea, Guanidinium hydrochloride, and heat, solvent, soda acid (potential of hydrogen 2-12) etc. has good resistance, and has heavy body.At first, the standard program that Padil thioesters or alanine thioesters are provided according to supplier under water-less environment is connected to Affi-Gel10 gel surface.Fusion rotein 2 is by the peptide expression plasmid pMFH of modified, in intestinal bacteria preparations (Su ZD and Ni F.Novel fusion proteinsfor efficient production of recombinant peptides.PCT/WO2004/015111).The N terminal design of reorganization fusion vector MFH has halfcystine so that can be with fusion rotein by the covalently bound surface to solid phase globule 1 of chemical connection method.In the present invention, three chemical hydrolysis sites, i.e. Met-Xaa (Xaa is an arbitrary amino acid), Asp-Pro and Asp-Gly are inserted between fusion vector and the glucagon kind polypeptide-1 individually.The fusion rotein of expressing is by Ni-NTA affinity chromatography column purification.Simply, the cytoclasis supernatant liquor is loaded into the Ni-NTA affinity chromatography post of crossing with cytoclasis damping fluid balance: 50 millimolar concentration phosphoric acid salt, 100 millimolar concentration sodium-chlor, 6 volumetric molar concentration hydrochloric acid guanidines, potential of hydrogen 8.0,10 volumetric molar concentration TECP.Use then and contain the aforementioned damping fluid thorough washing of 50 millimolar concentration imidozale affinity chromatography post.Fusion rotein is collected with the aforementioned buffer solution elution of the imidozale that contains 200 millimolar concentrations.Elutriant need not to be further purified and is directly used in chemistry and connects.In elutriant, add 4%benzymercaptan, with 4%thiophenol or 2%MESNA to increase the efficient that chemistry is connected.In the present invention, do not observe the difference between benzymercaptan and thiophenol combination and the MESNA, but the contriver prefers MESNA, because its odorlessness.The chemistry ligation connect fully at 6 hours.Use chemical hydrolysates to wash globule fully then: 0.1 volumetric molar concentration hydrochloric acid, 6 volumetric molar concentration hydrochloric acid guanidines.Add cyanogen bromide with 1: 200～400 mol ratios and decompose fusion rotein release polypeptide.When needs are used acid hydrolysis, use 50% formic acid to replace said hydrolyzed liquid.All hydrolysis reaction carry out for 25 ℃ in the dark with vibration mode mildly, and hydrolysis reaction is monitored with HPLC.Hydrolysis reaction efficient reached 95% later at 24 to 36 hours.Use earlier gravity wash-out hydrolyzed solution, then with the hydrolysis buffer solution elution solid phase globule of five times of bed volumes.Collection merges the elutant that contains polypeptide, uses the C18Sep-Pak reversed-phase column to carry out desalination.The characteristic of polypeptide is by the evaluation of MALDI-TOF mass spectrograph, as shown in Figure 4.The polypeptide productive rate of three kinds of hydrolysis method is summarized in table 8.
Embodiment 4: the amidated of glucagon kind polypeptide-1 analogue of the present invention
Peptide C terminal amido group changes the preparation of acyl ammonia react by enzyme process, removes blocking group with the light solution again.Fundamentally, with carboxypeptidase (carboxypeptidase) peptide substrate and nucleophilic reagent are carried out amidated.Changeing the acyl ammonia react generally carries out at aqueous buffer solutions (comprising 50mMHEPES and 5mMEDTA, potential of hydrogen 7.5 or 50mMCHES and 5mM EDTA, potential of hydrogen 9.5).Changeing acyl ammonia react process is monitored by HPLC.Thereafter, the potential of hydrogen of reaction mixture is reduced to potential of hydrogen be 1 to 3 with termination reaction.Changeing the acyl ammonia reaction product utilizes anti-phase spectrum color spectrometry HPLC to separate.
In addition, changeing the acyl ammonia react also can carry out in organic solution.Suitable organic solution can be used dimethylsulfoxide (DMSO), N, N '-dimethylacetamide, the solvent that dimethylformamdie is similar with other.Henriksen etc. have described methodology (Henriksen, D.B., Breddam, the K. ， ﹠amp of conventional organic solution transfer acyl ammonia react; Buchardt, O. (1993) .Peptide amidation by enzymatictransacylation and photolysis.Int.J.Pept.Protein Res.41,169-180.).
For example change the acyl ammonia react, peptide substrate mAla8GLP1 (7-36)-L-Ala is dissolved in 5% acetic acid solution with the aqueous solution.Nucleophilic reagent (as the L-LEU amide) is dissolved in the HEPES at 50mM, 5mM edta buffer solution (ultimate density is 500mM).25ul, the mAla8GLP1 of 40mM (7-36)-L-Ala mix (potential of hydrogen is 7.5,20 ℃) with the nucleophilic reagent of 950ul.The adding final concentration is 0.002 to 0.07 milligram every milliliter a carboxypeptidase.Changeing acyl ammonia react process is monitored by HPLC.After product no longer forms, add the trifluoroacetic acid termination reaction of a volume.
Change the product of acyl ammonia react, mAla8-GLP-1 (7-36)-ONPGA goes protection by photodissociation.Add 12.5ml 12.5ml be dissolved in methyl alcohol mAla8-GLP-1 (7-36)-ONPGA, 80mM NaHSO3 adjusts potential of hydrogen to 9.5 with 5N NaOH.With N2 reaction mixture was ventilated 15 minutes then, under nitrogen protection, carry out photolysis with UV-light subsequently.The photodissociation sample is 0,30, timing extraction analysis in 60 and 120 minutes.Utilize HPLC that each sample is analyzed, the result compares with standard model.
Embodiment 5: glucagon kind polypeptide-1 analogue of the present invention is to the activation of glucagon kind polypeptide-1 acceptor:
Present invention uses ordinary method (Montrose-Rafizadeh, C., Yang, H., Rodgers, B.D., Beday, A., Pritchette, the L.A. ， ﹠amp that is described by people such as Montrose-Rafizadeh; Eng, J. (1997) .High potency antagonists of the pancreaticglucagon-like peptide-1receptor.J.Biol.Chem.272,21201-21206.), the glucagon kind polypeptide-1 receptors bind of mensuration glucagon kind polypeptide-1 and analogue displacement CHO/GLP-1R cell [ 125I] competitive capacity of GLP-1.Before experiment, CHO/GLP-1R cell cultures to density is 70% back serum-free HAM ' S F-12 substratum washing 2h.After carrying out secondary washing with the 0.5ml damping fluid, cell places the 0.5ml damping fluid (to contain 2%BSA, 50mM DPP-IV inhibitor, 10mM glucose, 1-1,000nM GLP-1 or analogue and 30,000cpm 125I-glucagon kind polypeptide-1 and analogue) 4 ℃ of overnight incubation.Cultivate to finish, removing supernatant liquor, with ice-cold PBS washed cell three times.Add 0.5ml0.5N NaOH and 0.1%SDS in room temperature, and cultivated 10 minutes.The dose radiation of cell hydrolyzate is by in Apec series λ-counter measures.The specificity bonding force is decided to be to sum up makes a concerted effort to deduct the dose radiation of measuring with excessive cold glucagon kind polypeptide-1 (1 μ M).Its IC50 value is listed in table 7.
Embodiment 6: the mensuration of cAMP concentration in the cell
When the CHO/GLP-1R cell cultures when density is 60-70%, washed three times with phosphate buffered saline buffer.Add the phosphate buffered saline buffer that 1ML contains 0.1%BSA, put in the wet air brooder and cultivate 2h in 37 ℃.Continue to cultivate after adding the phosphate buffered saline buffer that 1ML contains 0.1%BSA and IBMX (1mM) then, and add glucagon kind polypeptide-1 and analogue.Blank sample replaces with phosphate buffered saline buffer.After 30 minutes, with three stopped reaction of ice-cold phosphate buffer wash cell.Handled 5 minutes with the ice-cold perchloric acid solution of 1ML (0.6M), extract the cAMP in the cell.With salt of wormwood (5M, the 84U1) potential of hydrogen to 7 of adjustment sample, short term oscillation sample hose, and the centrifugal throw out (5 minutes, 2000x g, 4 ℃) that goes.Supernatant liquor is dissolved in the Tris salt buffer (potential of hydrogen 7.5) that 0.05M contains 4MMEDTA after vacuum-drying.Add yellow soda ash (0.15 μ M) and zinc sulfate (0.15 μ M) in sample, be positioned over then 15 minutes on ice.The centrifugal throw out that desalts (5 minutes, 2000x g, 4 ℃).Use [ 3H] cAMP competition constraint analyrical reagent box (Amersham PharmaciaBiotech) working sample.EC 50Value list 7.
Embodiment 7: the anti-DPP IV of glucagon kind polypeptide-1 analogue of the present invention peptidase resistance is analyzed
Glucagon kind polypeptide-1 or analogue (ultimate density is 2uM) mix with DPP IV (1.25mU) or human plasma (7.5ul), and at 37 ℃, 50mM Tris-Cl damping fluid under the condition of potential of hydrogen 7.8, reacts 0,2,4,6 and 12h respectively.In preliminary experiment, determine the concentration of DPP IV and people's blood plasma, make polypeptide hydrolysis within 4-6h of about 50%, so that the hydrolytic process of in 12h, regularly observing polypeptide.Added TFA solution (15ul, 10% (v/v)) termination reaction.Reaction solution is (12,000 commentaries on classics/per minutes, 10 minutes) behind centrifugal clarification, use Vydac C18 to analyze the bigger peptide fragment (being GLP-1 (9-36) amide) of chromatography column quantitative assay hydrolysis.Analyze chromatography column and use TFA/H in advance 2O (0.12%) is balance (v/v), and flow velocity is 1.0ml/min.Use acetonitrile to carry out concentration gradient wash-out (from 10% to 40%, 30 minute).The absorption of sample peak uses the monitoring of 278 nano wave lengths, collects the back and uses the ESI mass spectrograph to identify.
Glucagon kind polypeptide-1 is 40min by DPP IV degradation half life (t1/2), and behind 12hrs, the 78-82% polypeptide is hydrolyzed, and main absorption peak is accredited as GLP-1 (9-36) small peptide through the ESI mass spectrograph.On the contrary, contain the glucagon kind polypeptide-1 analogue of non-peptide bond, i.e. mAla 8-GLP-1 (7-36)-NH2, mAla 8GLP1 (7-37) OH, mGly 8-GLP-1 (7-36)-NH2, mGly 8GLP1 (7-37) OH does not produce second absorption peak after reacting with DPP IV, show that hydrolysis has resistivity (Fig. 2 and table 7) completely to DPP IV.
As shown in Figure 2, if prolong N one terminal amino acid sequence of glucagon kind polypeptide-1 " GLP-1 (7-36) ", also can improve the resistivity of glucagon kind polypeptide-1 to DPP IV hydrolysis.Add Gly-Pro sequence (this sequence can be considered the acid hydrolysis products of Asp-Gly-Pro) and glucagon kind polypeptide-1 can be improved 3.7 times to the resistivity of DPP IV hydrolysis.Adding the Phe-Asn-Pro-Arg sequence can prolong the resistivity of glucagon kind polypeptide-1 to DPP IV hydrolysis above 24 hours.Compare with GLP-1 (7-37), other glucagon kind polypeptide-1 analogue has also improved the resistivity to DPP IV hydrolysis to some extent among the present invention.The detailed table 7 that the results are shown in.
Embodiment 8: the slowly-releasing analysis of glucagon kind polypeptide-1 analogue
The slowly-releasing analysis is carried out in the following way.The target glucagon kind polypeptide-1 analogue according to a conventional method with the human albumin covalent cross-linking.Crosslinking protein is dissolved in 50 millimolar concentration phosphoric acid buffers (final concentration is 1 millimolar concentration).1 milliliter of crosslinking protein solution is moved into Float ALyzer TMDialysis tubing (1 milliliter, MWCO:10KD).Dialysis tubing is inserted in the phosphoric acid buffer test tube that 3 milliliters of same concentration are housed, dialysis tubing should immerse in the damping fluid fully, and at the uniform velocity stirs with magnetic stirring apparatus again.Every the time extract the dosage that measured in solution dialysis tubing in the test tube discharges glucagon kind polypeptide-1 analogue.In simultaneous test, add low dose of human thrombin (thrombin) and pepx IV (DPP IV) respectively, to measure the glucagon kind polypeptide-1 analogue slow release effect.The glucagon kind polypeptide-1 that contains 1 millimolar concentration in the blank test is similar.Experimental result shows: crosslinking protein people-glucagon kind polypeptide-1 analogue has tangible slow release effect under zymoplasm or DPP IV effect, as shown in Figure 5.
Table 1, glucagon kind polypeptide-1 aminoacid sequence
? Aminoacid sequence Amino acid sequence SEQ?ID?NO：?
GLP-1(7-36)-NH 2 His-Aal-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 1?
GLP-1(7-37)-OH? His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 2?
The glucagon kind polypeptide-1 aminoacid sequence of table 2, the variation of the 8th amino acids
? Aminoacid sequence Amino acid sequence SEQ?ID?NO：?
Cys 8-GLP-1(7-36)-NH 2 His-Cys-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 3?
Cys 8-GLP-1(7-37)-OH? His-Cys-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 4?
Cys(SO 3) 8-GLP-1(7-36)-NH 2 His-Cys(SO 3)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 5?
Cys(SO 3) 8-GLP-1(7-37)-OH His-Cys(SO 3)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 6?
Cys(Acm) 8-GLP-1(7-36)-NH 2 His-Cys(Acm)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 7?
Cys(Acm) 8-GLP-1(7-37)-OH His-Cys(Acm)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 8?
βAla 8-GLP-1(7-36)-NH 2 His-βAla-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 9?
βAla 8-GLP-1(7-37)-OH His-βAla-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe- 10?
? Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH ?
mAla 8-GLP-1(7-36)-NH 2 His-{NH-CH(CH 3)-CH 2}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 11?
mAla 8-GLP-1(7-37)-OH His-{NH-CH(CH 3)-CH 2}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 12?
mGly 8-GLP-1(7-36)-NH 2 His-{NH-CH 2-CH 2}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 13?
mGly 8-GLP-1(7-37)-OH His-{NH-CH 2-CH 2}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 14?
The glucagon kind polypeptide-1 aminoacid sequence of table 3, the preparation of available gene recombination technology
? Aminoacid sequence Amino acid sequence SEQ?ID?NO：?
GLP-1(7-36)-Met? His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-GlyArg-Met 15?
GLP-1(7-36)-hSer? His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-hSer 16?
Gly 8-GLP-1(7-36)-Met His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Met 17?
Gly 8-GLP-l(7-36)-hSer His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-hSer 18?
Gly 5，Pro 6-GLP-1(7-37)-Asp-OH Gly-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-Asp-OH 19?
Gly 5，Ala 6-GLP-1(7-37)-Asp-OH Gly-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-Asp-OH 20?
Pro 5，Ala 6-GLP-1(7-37)-Asp-OH Pro-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-Asp-OH 21?
Pro 5，Pro 6-GLP-1?(7-37)-Asp-OH? Pro-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val- Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-Asp-OH 22?
Table 4, ring-type glucagon kind polypeptide-1 aminoacid sequence
? Aminoacid sequence Amino acid sequence SEQ?ID?NO：?
Cyclized-Gly 5，Pro 6，Asp 37-GLP-1(7-36) Gly-Pro-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-|Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-|Ala-Trp-Leu-Val-Lys-Gly-Arg-Asp-|-------------------------------------| 23?
Cyclized-Gly 5，Ala 6，Asp 37-GLP-1(7-36) -Gly-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-|Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-|Ala-Trp-Leu-Val-Lys-Gly-Arg-Asp-|-----------------------------------------| 24?
Cyclized-Pro 5，Pro 6，Asp 37-GLP-1(7-36) Pro-Pro-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-|Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-|Ala-Trp-Leu-Val-Lys-Gly-Arg-Asp-|------------------------------------------| 25?
Cyclized-Pro 5，Ala 6，Asp 37-GLP-1(7-36) -Pro-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-|Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-|Ala-Trp-Leu-Val-Lys-Gly-Arg-Asp-|--------------------------------------------| 26?
Table 5, be used for the crosslinked glucagon kind polypeptide-1 aminoacid sequence of albumin
? Aminoacid sequence Amino acid sequence SEQ?ID?NO：?
Phe-Asn-Pro-Arg-GLP-1(7-37)-OH? Phe-Asn-Pro-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 27?
Leu-Val-Pro-Arg-Gly 5，Ser 6-GLP-1(7-37)-Asp-OH? Leu-Val-Pro-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 28?
Phe-Asn-Pro-Arg-Gly 5，Ser 6-GLP-1(7-37)-OH? Phe-Asn-Pro-Arg-Gly-Ser-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 29?
Leu-Val-Pro-Arg-Gly 5，Ser 6-GLP-1(7-37)-Asp-OH? Leu-Val-Pro-Arg-Gly-Ser-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 30?
Phe-Asn-Pro-Arg-Gly 5，Pro 6-GLP-1(7-37)-OH? Phe-Asn-Pro-Arg-Gly-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 31?
Leu-Val-Pro-Arg-Gly 5， Leu-Val-Pro-Arg-Gly-Pro-His-Ala-Glu-Gly-Thr-Phe- 32
?
Pro 6-GLP-1(7-37)-Asp-OH Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH ?
Phe-Asn-Pro-Arg-Gly 5，Pro 6-GLP-1(7-37)-OH? Phe-Asn-Pro-Arg-Gly-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 33?
Phe-Asn-Pro-Arg-Gly 5，Ala 6-GLP-1(7-37)-OH? Phe-Asn-Pro-Arg-Gly-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 34?
Cys 5，Ala 6-GLP-1(7-37)-OH? Cys-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 35?
Cys 5，Pro 6-GLP-1(7-37)-OH? Cys-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 36?
Table 6, dimer glucagon kind polypeptide-1 aminoacid sequence
? Aminoacid sequence Amino acid sequence SEQ?IDNO：
di-Cys 5，Ala 6-GLP-1(7-37)-OH? Cys-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-|Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-|Leu-Val-Lys-Gly-Arg-Gly-OH|Cys-Ala-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 37?
di-Cys 5，Pro 6-GLP-1(7-37)-OH? Cys-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-|Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-|Leu-Val-Lys-Gly-Arg-Gly-OH|Cys-Pro-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 38?
di-Cys 8-GLP-1(7-37)-OH His-Cys-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-|Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-|Leu-Val-Lys-Gly-Arg-Gly-OH|His-Cys-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH 39?
Acceptor binding force and cAMP analysis and the anti-DPPIV analysis in CHO/GLP-1R of table 7, glucagon kind polypeptide-1 and derivative
SEQ?ID?NO? Peptide? Receptor?bindingIC 50(nM) cAMP?productionEC 50(nM) DPP?IV?digestionassay?t 1/2
1 GLP-1(7-36)-NH 2 0.3±0.06 3.1±0.8 36±5min
2 GLP-1(7-37)-OH 2.4±0.6 20±2.1 45±4min
3 Cys 8-GLP-1(7-36)-NH 2 154.0±25 300.3±54 >12hrs
4 Cys 8-GLP-1(7-37)-OH 213.0±30 545.3±65 >12hrs
5 Cys(SO 3) 8-GLP-1(7-36)-NH 2 ND ND >12hrs
6 Cys(SO 3) 8-GLP-1(7-37)-OH ND ND >12hrs
7 Cys(Acm) 8-GLP-1(7-36)-NH 2 ND ND >12hrs
8 Cys(Acm) 8-GLP-1(7-37)-OH ND ND >12hrs
9 βAla 8-GLP-1(7-36)-NH 2 ND ND >12hrs
10 βAla 8-GLP-1(7-37)-OH 36.0±2.3 105.3±10.8 >12hrs
11 mAla 8-GLP-1(7-36)-NH 2 0.8±0.03 4.0±0.12 No?digestion
12 mAla 8-GLP-1(7-37)-OH 1.8±0.4 2.3±0.6 No?digestion
13 mGly 8-GLP-1(7-36)-NH 2 4.2±0.5 54.3±4.1 No?digestion
14 mGly 8-GLP-1(7-37)-OH 6.2±0.6 32.3±2.8 No?digestion
15 GLP-1(7-36)-Met 5.8±0.3 76±12 45±6min
16 GLP-1(7-36)-hSer 18.8±0.3 156±32 42±7min
17 Gly 8-GLP-1(7-36)-Met ND ND 58±6min
18 Gly 8-GLP-1(7-36)-hSer ND ND 63±7min
19 Gly 5，Pro 6-GLP-1(7-37)-Asp-OH 134±11 265±32 150±7min
20 Gly 5，Ala 6-GLP-1(7-37)-Asp-OH 176±12 287±30 170±10min
21 Pro 5，Ala 6-GLP-1(7-37)-Asp-OH 243±20 145±23 124±12min
22 Pro 5，Pro 6-GLP-1(7-37)-Asp-OH 176±12 287±30 135±15min
23? Cyclized-Gly 5，Pro 6，Asp 37-GLP-1(7-36) 346±12? >1000? No?digestion?
24? Cyclized-Gly 5，Ala 6，Asp 37-GLP-1(7-36) 378±15? >1000? No?digestion?
25? Cyclized-Pro 5，Pro 6，Asp 37-GLP-1(7-36) 413±17? >1000? No?digestion?
26? Cyclized-Pro 5，Ala 6，Asp 37-GLP-1(7-36) 215±13? >1000? No?digestion?
27 Phe-Asn-Pro-Arg-GLP-1(7-37)-OH 4.2±0.6 22.3±2.5 >24hrs
28? Leu-Val-Pro-Arg-Gly 5，Ser 6-GLP-1(7-37)-Asp-OH 17.2±2.1? 52.3±9? >24hrs?
29? Phe-Asn-Pro-Arg-Gly 5，Ser 6-GLP-1(7-37)-OH 15.2±2.3? 62.3±8? >24hrs?
?
30? Leu-Val-Pro-Arg-Gly 5，Ser 6-GLP-1(7-37)-Asp-OH 57.2±2.1? 162.3±29? >24hrs?
31? Phe-Asn-Pro-Arg-Gly 5，Pro 6-GLP-1(7-37)-OH 98.2±11? 192.6±25? >24hrs?
32? Leu-Val-Pro-Arg-Gly 5，Pro 6-GLP-1(7-37)-Asp-OH 27.2±2.5? 32.3±7? >24hrs?
33? Phe-Asn-Pro-Arg-Gly 5，Pro 6-GLP-1(7-37)-OH 17.2±2.1? 52.3±9? >24hrs?
34? Phe-Asn-Pro-Arg-Gly 5，Ala 6-GLP-1(7-37)-OH 17.2±2.1? 52.3±9? >24hrs?
35 Cys 5，Ala 6-GLP-1(7-37)-OH 214±21 134±11 265±32min
36 Cys 5，Pro 6-GLP-1(7-37)-OH 430±32 246±28 62±4min
37 di-Cys 5，Ala 6-GLP-1(7-37)-OH 178±16 390±25 >24hrs
38 di-Cys 5，Pro 6-GLP-1(7-37)-OH 156±14 410±34 >24hrs
39 di-Cys 8-GLP-1(7-37)-OH 210±16 157±32 >24hrs
The comparison that table 8, three kinds of hydrolysis method prepare glucagon kind polypeptide-1
Figure S051A2363720051230D000181

Claims (2)

1. glucagon kind polypeptide-1 analogue, it is characterized in that: the aminoacid sequence of described glucagon kind polypeptide-1 analogue is as follows:
His-Xaa 8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Xaa 37
Or the acceptable salt of pharmacology;
Wherein:
Xaa 8Be-NH-CH 2-CH 2-;
Xaa 37Be Gly-OH or NH 2
2. the described glucagon kind polypeptide-1 analogue of claim 1 is used for the treatment of application in the slow releasing pharmaceutical of diabetes B in preparation.
CN 200510102363 2005-12-16 2005-12-16 Glucagon kind polypeptide-1 analogue, its preparation method and application Expired - Fee Related CN1786031B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200510102363 CN1786031B (en) 2005-12-16 2005-12-16 Glucagon kind polypeptide-1 analogue, its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200510102363 CN1786031B (en) 2005-12-16 2005-12-16 Glucagon kind polypeptide-1 analogue, its preparation method and application

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010291350XA Division CN101985470B (en) 2005-12-16 2005-12-16 Glucagon-like polypeptide-1 analog, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN1786031A CN1786031A (en) 2006-06-14
CN1786031B true CN1786031B (en) 2011-05-25

Family

ID=36783648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200510102363 Expired - Fee Related CN1786031B (en) 2005-12-16 2005-12-16 Glucagon kind polypeptide-1 analogue, its preparation method and application

Country Status (1)

Country Link
CN (1) CN1786031B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020087305A1 (en) 2018-10-30 2020-05-07 刘建宁 Glp-1 polypeptide having glp-1 receptor agonist activity and uses thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101337989B (en) * 2008-08-28 2012-10-24 中国药科大学 Novel glucagon-like peptide-1(GLP-1) analogues and use thereof
CN102718858B (en) * 2011-03-29 2014-07-02 天津药物研究院 Glucagon-like peptide-1 (GLP-1) analogue monomer and dimer, preparation method therefor and application thereof
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CN102180963B (en) * 2011-04-22 2014-06-25 中国药科大学 Glucagons like peptide-1 (GLP-1) analog and application thereof
CN102363633B (en) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof
CN103087179A (en) * 2012-11-30 2013-05-08 中国药科大学 Long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof
CN103087176A (en) * 2012-11-30 2013-05-08 中国药科大学 Long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof
CN103087175A (en) * 2012-11-30 2013-05-08 中国药科大学 Novel long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof
CN103087178A (en) * 2012-11-30 2013-05-08 中国药科大学 Long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof
CN103087177A (en) * 2012-11-30 2013-05-08 中国药科大学 Long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof
CN104098702B (en) * 2014-07-23 2017-06-16 湖北工业大学 One kind prepares the polypeptides of GLP 1 or its analog methods and applications using MFH fusion proteins
CN111349155B (en) * 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 Glucagon analogue and preparation method and application thereof
CN113462713B (en) * 2021-09-06 2021-12-07 中国农业科学院生物技术研究所 Method for improving expression level of glucagon-like peptide hexa-linked peptide in pichia pastoris

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020087305A1 (en) 2018-10-30 2020-05-07 刘建宁 Glp-1 polypeptide having glp-1 receptor agonist activity and uses thereof
US11141464B2 (en) 2018-10-30 2021-10-12 Liu Jianning GLP-1 polypeptide having GLP-1 receptor agonist activity and use thereof

Also Published As

Publication number Publication date
CN1786031A (en) 2006-06-14

Similar Documents

Publication Publication Date Title
CN1786031B (en) Glucagon kind polypeptide-1 analogue, its preparation method and application
US6767887B1 (en) Exendin analogues, processes for their preparation and medicaments containing them
CN101985470B (en) Glucagon-like polypeptide-1 analog, preparation method and application thereof
AU2003200839B2 (en) Extended glucagon-like peptide-1 analogs
US20100267610A1 (en) Polypeptide comprising a knottin protein moiety
AU2009335712B2 (en) Insulin analogs
CN102088989B (en) Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers
US7329646B2 (en) Derivatives of the insulinotropic peptide exendin-4 and methods of production thereof
CN104302772B (en) Albumen, protein conjugate and its application for treating diabetes
RU2302882C2 (en) Method for preparing insulin or insulin derivatives with correctly joined cystine bridges
Karas et al. The chemical synthesis of insulin: an enduring challenge
Moroder et al. Insulin—from its discovery to the industrial synthesis of modern insulin analogues
CA2468100A1 (en) Insulin molecule having protracted time action
AU2002313869B2 (en) A method of producing glucagon-like peptide 1(GLP-1)7-36 and an GLP-1 analogue
US11447535B2 (en) GLP-1 analogues
US20100021480A1 (en) Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
CN110305223A (en) The method that recombination fused in tandem albumen prepares target polypeptides
CN113493504A (en) Molecular modification of GIP-Exendin-4 chimeric peptide and application of dimer thereof in treating diabetes
CN102311501A (en) Fusion protein comprising GLP-1 (Glucagon-Like Peptide) or analog thereof and preparation method as well as application thereof
CN106084031B (en) Application of GLP-1R/GCGR dual agonist in medicines for reducing blood sugar and losing weight
Dawson Synthesis of chemokines by native chemical ligation
US5424394A (en) Synthetic preparation of amylin and amylin analogues
CN102453095A (en) Fusion protein containing GLP (glucagon-like peptide)-1 and preparation method and application thereof
Reymond et al. Truncated, branched, and/or cyclic analogs of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands
CN111269312B (en) Heterologous fusion protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110525

Termination date: 20131216